Delamanid Access Widened But TB Groups Want More
This article was originally published in PharmAsia News
Executive Summary
Otsuka has agreed a plan with the Global Drug Facility to improve the worldwide distribution of its novel TB drug delamanid, but several access groups are asking for additional action to combat the multidrug-resistant form of the disease.
You may also be interested in...
Call For India Compulsory Licenses For Last Resort TB Drugs
Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses.
Indian Teen’s Fight For Lifesaving TB Drug Highlights Access Issues
An Indian teenager’s court battle for a new tuberculosis drug that doctors say could save her life has cast a harsh spotlight on the slow rollout of breakthrough medicines to treat the disease in the country, one of the world’s biggest TB hotspots.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.